Primary Cytoreductive Surgery Versus Interval Debulking Surgery Following Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer: An Institutional Review

被引:2
|
作者
Ahmad, Zeeshanuddin [1 ]
Jain, Amar [1 ]
Mehta, Nikhil [1 ]
Saldanha, Elroy [1 ]
Patel, Dhruv [1 ]
Desai, Sanjay M. [1 ]
机构
[1] Sri Aurobindo Med Coll & Post Grad Inst, Dept Surg Oncol, Indore, Madhya Pradesh, India
关键词
Epithelial ovarian cancer (EOC); Primary cytoreductive surgery (PCS); Interval debulking surgery (IDS); Neoadjuvant chemotherapy (NACT); ADVANCED-STAGE OVARIAN; EXPLORATORY ANALYSIS; SURVIVAL; CARCINOMA; TIME;
D O I
10.1007/s40944-018-0253-2
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
ObjectiveTo compare theoverall survival of women with advanced-stage EOC treated by PCS versus NACT followed by IDS.Design, Setting, and ParticipantsRetrospective study of women with stage IIB-IVA ovarian carcinoma FIGO staging diagnosed between 2016 and 2018 treated at Department of Surgical Oncology, Sri Aurobindo Medical College and Post Graduate Institute, Indore.ExposuresInitial treatment approach of PCS versus NACT+IDS, examined using an intent-to-treat analysis.ResultsThe median follow-up was 18months (10-36months) in both groups. The median overall survival was 38months in PCS group and 31months in NACT group. Postoperative complications were seen more often in PCS group (11.3%) against 3.33% in NACT group. Patients with residual disease (microscopic and macroscopic residual disease) had poorer prognosis.ConclusionsPrimary cytoreductive surgery is associated with improved survival compared with NACT in otherwise healthy women with bulky epithelial ovarian. The biggest risk associated with the use of NACT is that patients with significant side effects and refractory disease will lose the opportunity for initial surgery. The lower survival in women receiving NACT can be owed to limited performance status in women undergoing NACT.
引用
收藏
页数:4
相关论文
共 50 条
  • [41] Neoadjuvant Chemotherapy or Primary Debulking Surgery for Stage IIIC Ovarian Cancer
    Copur, Mehmet Sitki
    Gauchan, Dron
    Ramaekers, Ryan
    Crockett, David
    Clark, Douglas
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07) : 802 - 802
  • [42] Minimally invasive interval debulking surgery after neoadjuvant chemotherapy for ovarian cancer
    Seagle, B. L. L.
    Yang, J.
    Kocherginsky, M.
    Shahabi, S.
    GYNECOLOGIC ONCOLOGY, 2018, 149 (03) : 629 - 630
  • [43] Laparoscopic interval debulking surgery for advanced ovarian cancer after neoadjuvant chemotherapy
    Jorgensen, K.
    Melamed, A.
    Bradford, L.
    Wang, V.
    Chang, H.
    Rauh-Hain, J. A.
    Schorge, J.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 49 - 50
  • [44] The management of epithelial ovarian cancer: neoadjuvant chemotherapy and interval surgery
    Allen, D. G.
    SOUTHERN AFRICAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2010, 2 (02) : 67 - 68
  • [45] ROLE OF ROBOTIC SURGERY FOR INTERVAL DEBULKING OF OVARIAN CANCER AFTER NEOADJUVANT CHEMOTHERAPY
    Press, J.
    Bondurant, A.
    Drescher, C.
    Musa, F.
    Shah, C.
    Veljovich, D.
    Kretzer, N.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A135 - A135
  • [46] Delays from neoadjuvant chemotherapy to interval debulking surgery and survival in ovarian cancer
    Liu, Ying L.
    Zhou, Qin C.
    Iasonos, Alexia
    Filippova, Olga T.
    Chi, Dennis S.
    Zivanovic, Oliver
    Sonoda, Yukio
    Gardner, Ginger
    Broach, Vance
    OCearbhaill, Roisin
    Konner, Jason A.
    Aghajanian, Carol A.
    Long, Kara
    Tew, William
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 (10) : 1554 - 1561
  • [47] Laparoscopic interval debulking surgery after neoadjuvant chemotherapy in advanced ovarian cancer
    Nitecki, R.
    Melamed, A.
    Boruta, D. M., II
    del Carmen, M. G.
    Clark, R. M.
    Growdon, W. B.
    Goodman, A.
    Schorge, J. O.
    Rauh-Hain, J. A.
    GYNECOLOGIC ONCOLOGY, 2017, 145 : 125 - 125
  • [48] NEOADJUVANT CHEMOTHERAPY VERSUS PRIMARY DEBULKING SURGERY IN FIGO STAGE III AND IV EPITHELIAL OVARIAN, TUBAL OR PERITONEAL CANCER
    Tzanis, A.
    Iavazzo, C. R.
    Hadjivasilis, A.
    Tsouvali, H.
    Antoniou, G.
    Antoniou, S.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A296 - A296
  • [49] Pattern of recurrence after interval cytoreductive surgery and HIPEC following neoadjuvant chemotherapy in primary advanced stage IIIC/IVA epithelial ovarian cancer
    Sinukumar, Snita
    Damodaran, Dileep
    Ray, Mukurdipi
    Mehta, Sanket
    Paul, Lista
    Bhatt, Aditi
    EJSO, 2021, 47 (06): : 1427 - 1433
  • [50] Upfront cytoreductive surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer in Indian patients
    Ray, Mukur Dipi
    Deo, Suryanarayana S. V.
    Kumar, Lalit
    Gaur, Manish Kumar
    FUTURE ONCOLOGY, 2021, 17 (27) : 3607 - 3614